MTOR and cancer: Since there have been several case reports addressing the clinical efficacy of phenothiazine derivatives in cancer patients [37, 39], the clinical use of thioridazine as a targeting agent of PI3K/Akt/mTOR signaling pathway may not be unrealistic when these concerns are resolved by further research.